LOGIN  |  REGISTER
Assertio
Assertio

Procaps to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

November 10, 2023 | Last Trade: US$2.51 0.07 2.87
  • Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time

MIAMI & BARRANQUILLA, Colombia / Nov 10, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023.

The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results.

To access the call, please use the following information:

Date:

 

Thursday, November 16, 2023

Time:

 

10:30 a.m. ET

Webcast:

 

Click here to access

Toll Free dial-in number:

 

1-844-204-8586

Toll/International dial-in number:

 

1-412-317-6346

HD Web Phone:

 

Click here

Conference ID:

 

Procaps Group

The conference call will be broadcast live and available for replay here and via Procaps’ investor relations website.

A telephone replay will be available approximately two hours after the call and will run through November 23, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 4127390.

About Procaps Group

Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

For more information, visit Procaps’ investor relations website investor.procapsgroup.com.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB